Login to Your Account

Kala Pharmaceuticals Inc. has completed a $22.5 million financing to fund four trials of the company's mucous-penetrating nanoparticle platform and its lead application in fighting inflammation after cataract surgery.
Neos Therapeutics Inc.'s upsized series C financing – from $15.5 million to $18 million – along with a $20 million loan facility with Hercules Technology Growth Capital Inc. means the firm will "not only have enough money to hit the key regulatory milestones over the next 12-15 months, but to give us financial flexibility into 2016," said Victor Miller, vice president of finance.
Principia Biopharma Inc. has raised $50 million to advance the company's pipeline of small-molecule autoimmune and oncology therapies into clinical testing. Sofinnova Ventures led the funding, citing strong preclinical validation of Principia's pipeline and its prolific drug discovery engine.
More FINANCINGS Headlines

Cast Your Vote

Has biotech’s bubble burst?: